Hepatokines: unlocking the multi-organ network in metabolic diseases
Hepatokines: unlocking the multi-organ network in metabolic diseases
复制标题
DOI：
10.1007/s00125-015-3634-4
复制
发表时间：
2015-08-01
期刊：
影响因子：
8.2
通讯作者：
Postic, Catherine
中科院分区：
文献类型：
--
作者：
Iroz, Alison;Couty, Jean-Pierre;Postic, Catherine
面对城市化、能量摄入过剩、久坐不动的习惯和肥胖，2型糖尿病已发展成为全球主要的健康问题。肝脏在当代肥胖研究中经常被忽视，它正在成为全身能量稳态的中央调节器。肝源性蛋白被称为肝因子，现在被认为是开发新型2型糖尿病治疗的有吸引力的靶点。本评论介绍了三种主要肝因子的例子：胎儿素a，首先被描述并与炎症和胰岛素抵抗增加相关；血管生成素样蛋白（ANGPTL）8/ β atrophin，最初被认为对β细胞增殖有作用，尽管这种作用最近受到质疑；成纤维细胞生长因子21 (FGF21)，一种胰岛素增敏激素，由于其有益的代谢作用而成为一个吸引人的药物靶点。肝因子研究的新发现可能为代谢紊乱和2型糖尿病带来有希望的生物标志物和治疗方法。
In the face of urbanisation, surplus energy intake, sedentary habits and obesity, type 2 diabetes has developed into a major health concern worldwide. Commonly overlooked in contemporary obesity research, the liver is emerging as a central regulator of whole body energy homeostasis. Liver-derived proteins known as hepatokines are now considered attractive targets for the development of novel type 2 diabetes treatments. This commentary presents examples of three leading hepatokines: fetuin-A, the first to be described and correlated with increased inflammation and insulin resistance; angiopoietin-like protein (ANGPTL)8/betatrophin, initially proposed for its action on beta cell proliferation, although this effect has recently been brought into question; and fibroblast growth factor 21 (FGF21), an insulin-sensitising hormone that is an appealing drug target because of its beneficial metabolic actions. Novel discoveries in hepatokine research may lead to promising biomarkers and treatments for metabolic disorders and type 2 diabetes.